(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Abeona Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ABEO's revenue for 2025 to be $1,422,771,142, with the lowest ABEO revenue forecast at $1,073,779,889, and the highest ABEO revenue forecast at $1,614,506,588. On average, 4 Wall Street analysts forecast ABEO's revenue for 2026 to be $6,166,535,271, with the lowest ABEO revenue forecast at $5,504,464,794, and the highest ABEO revenue forecast at $6,668,280,538.
In 2027, ABEO is forecast to generate $10,035,212,274 in revenue, with the lowest revenue forecast at $9,929,522,458 and the highest revenue forecast at $10,231,347,200.